Literature DB >> 1683154

Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease.

H L Grierson1, J Skare, J Hawk, M Pauza, D T Purtilo.   

Abstract

Patients with X-linked lymphoproliferative (XLP) disease are characterized by extreme vulnerability to Epstein-Barr virus (EBV). Following infection with EBV, affected males develop fatal infectious mononucleosis (IM), hypogammaglobulinemia (H), or non-Hodgkin's lymphoma (NHL). In addition, hyper IgM, red cell aplasia, necrotizing lymphoid vasculitis (NLV), and aplastic anemia occur rarely. The recent use of DNA restriction fragment length polymorphism (RFLP) probes in linkage with the XLP gene now permit detection of affected males prior to primary EBV infection. We have measured immunoglobulin class and subclass levels in sera from EBV-negative males who were either positive or negative for the XLP genotype by RFLP analysis. Elevated IgA or IgM and/or variable deficiency of IgG, IgG1, and IgG3 occurred in the sera of 13/13 RFLP-positive, EBV-negative males. No consistent abnormalities were noted in 14 RFLP-negative, EBV-negative males. We conclude that the immune defect in XLP is not solely EBV-specific, although EBV is responsible for most of the morbidity and all of the mortality. Further, serial measurement of Ig levels may provide information regarding status of EBV-negative males at risk where RFLP analysis is uninformative or in families where sporadic cases of fatal IM, acquired hypogammaglobulinemia or NHL have occurred, but wherein the genotype of XLP cannot be documented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683154     DOI: 10.1002/ajmg.1320400309

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  13 in total

1.  Defective B cell responses in the absence of SH2D1A.

Authors:  Massimo Morra; Robert A Barrington; Ana C Abadia-Molina; Susumo Okamoto; Aimee Julien; Charles Gullo; Anuj Kalsy; Matthew J Edwards; Gang Chen; Rosanne Spolski; Warren J Leonard; Brigitte T Huber; Persephone Borrow; Christine A Biron; Abhay R Satoskar; Michael C Carroll; Cox Terhorst
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-17       Impact factor: 11.205

Review 2.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP.

Authors:  M J Czar; E N Kersh; L A Mijares; G Lanier; J Lewis; G Yap; A Chen; A Sher; C S Duckett; R Ahmed; P L Schwartzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

4.  X-linked lymphoproliferative disease: three atypical cases.

Authors:  K Nistala; K C Gilmour; T Cranston; E G Davies; D Goldblatt; H B Gaspar; A M Jones
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

Review 5.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

6.  Intronic SH2D1A mutation with impaired SAP expression and agammaglobulinemia.

Authors:  Mike Recher; Ari J Fried; Michel J Massaad; Hye Young Kim; Michela Rizzini; Francesco Frugoni; Jolan E Walter; Divij Mathew; Hermann Eibel; Christoph Hess; Silvia Giliani; Dale T Umetsu; Luigi D Notarangelo; Raif S Geha
Journal:  Clin Immunol       Date:  2012-12-07       Impact factor: 3.969

Review 7.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

8.  Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome.

Authors:  K E Nichols; D P Harkin; S Levitz; M Krainer; K A Kolquist; C Genovese; A Bernard; M Ferguson; L Zuo; E Snyder; A J Buckler; C Wise; J Ashley; M Lovett; M B Valentine; A T Look; W Gerald; D E Housman; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine.

Authors:  E F Posthuma; R G Westendorp; A van der Sluys Veer; J C Kluin-Nelemans; P M Kluin; C B Lamers
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

Review 10.  Immune regulation in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows; D J Moss
Journal:  Microbiol Rev       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.